The present invention features methods for treating or ameliorating tissue damage using intravenous administration of compositions (for example, isolated peptide compositions or stem cells expressing such peptides) that include stromal cell derived factor-1 (SDF-1) peptides or mutant SDF-1 peptides that have been mutated to make them resistant to protease digestion, but which retain chemoattractant activity.
